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Cardiovascular risk in chronic kidney disease. National Kidney
Foundation guidelines define chronic kidney disease (CKD) as
persistent kidney damage (confirmed by renal biopsy or mark-
ers of kidney damage) and/or glomerular filtration rate (GFR)
<60 mL/min/1.73m2 for greater than three months.
Patients with CKD experience higher mortality and adverse
cardiovascular (CV) event rates, which remains significant after
adjustment for conventional coronary risk factors. This progres-
sive CV risk associated with worsening renal function may be
explained by other factors that become increasingly important
with renal decline. In this regard, more investigation of noncon-
ventional factors that have received a lot of attention includes
associations with inflammation, albuminuria, reduced vascular
compliance, and homocysteine.
In addition, individuals with CKD encounter the problem of
“therapeutic nihilism,” in which there is a lack of appropriate
risk factor modification and intervention, despite established
awareness of their high cardiovascular risk. Several studies sug-
gest that these individuals derive as much, if not more, benefit
from evidence-based cardiovascular therapies and strategies.
Greater educational efforts are needed to reduce this thera-
peutic gap.
A large population of individuals entering the tran-
sition phase toward end-stage renal disease (ESRD) is
emerging. National Kidney Foundation guidelines de-
fine these individuals as having chronic kidney dis-
ease (CKD) [1]. CKD is defined as persistent kidney
damage (confirmed by renal biopsy or markers of kid-
ney damage) and/or glomerular filtration rate (GFR)
<60 mL/min/1.73m2 for greater than three months [1].
Using these criteria, current estimates account for at least
11 million individuals and rising [1].
Many community-based studies have documented that
individuals with CKD have a rising prevalence of cardio-
vascular (CV) disease associated with progressive renal
decline [2–5]. A higher rate of adverse CV events is noted
among this cohort when compared with those with nor-
mal renal function [5–7]. Indeed, although there has been
an appropriate emphasis on reducing the risk of progres-
sion to dialysis of patients with CKD, these individuals
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are much more likely to die from cardiovascular causes
[8].
EPIDEMIOLOGY
Evidence for increasing CVD morbidity and mortal-
ity tracking with mild to moderate renal dysfunction has
mainly stemmed from community-based studies. These
have included the Framingham Heart study, NHANES I,
ARIC, and the Hoorn studies [8–11]. All of these stud-
ies documented an inverse relationship between renal
function and risk of an adverse cardiovascular outcome
[8–11].
The influence of mild to moderate renal impairment
post acute coronary syndrome has been shown to in-
crease cardiovascular mortality and morbidity at 30 and
180 days [12–15]. Longer-term outcome data related to
a broader spectrum of renal dysfunction have been lim-
ited, partly related to smaller cohorts and exclusion of
individuals with renal dysfunction. Studies that have ex-
amined the relationship between renal function and car-
diovascular outcomes among high CV risk cohorts with
left ventricular dysfunction with longer follow-up have
included the Studies of Left Ventricular Dysfunction
(SOLVD), Trandolapril Cardiac Evaluation (TRACE),
Survival and Ventricular Enlargement (SAVE), and Val-
sartan in Acute Myocardial Infarction (VALIANT) trials
[16–18] (Table 1). Although these studies excluded indi-
viduals with baseline serum creatinine of ≥2.5 mg/dL,
approximately a third of patients had CKD based upon
National Kidney Foundation estimated glomerular fil-
tration rate (eGFR) criteria [1]. In all of these studies,
reduced renal function was associated with significantly
higher mortality and adverse CV event rates independent
of other comorbidities, with an especially marked rise in
event rates below an eGFR of 60 mL/min/1.73m2 (Fig. 1);
any short-term risk conferred at baseline also persisted
in the longer term following acute myocardial infarction
(AMI).
Why increased cardiovascular risk in chronic
kidney disease?
Mechanisms as to why renal dysfunction portends
increased CV risk are still being elucidated. Several
S-11
S-12 Anavekar and Pfeffer: Cardiovascular risk in chronic kidney disease
Table 1. Influence of baseline renal function on cardiovascular
outcomes in cohorts with left ventricular dysfunction
Hazard ratio for CV
events for every 10 mL/
Number of min/1.73m2 decrease in
Trial Year patients baseline eGFR
Studies of Left 2001 6635 1.1
Ventricular
Dysfunction (SOLVD)
Trandolapril Cardiac 2002 6252 1.2
Evaluation (TRACE)
Survival And Ventricular 2003 2184 1.5
Enlargement (SAVE)
Valsartan in Acute 2003 14527 1.1
Myocardial Infarction
Trial (VALIANT)
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Fig. 1. Hazard ratio for CV events with declining eGFR in VALIANT.
From Anavekar et al, N Engl J Med, 2004.
explanations have been provided, inclusive of high pro-
portions of coronary risk factors and comorbidities [2,
19]. Increasing expression of nonconventional risk fac-
tors that may be acting alone or synergistically with ex-
isting coronary risks, and lack of appropriate risk factor
modification and intervention are all considered to be
contributing factors.
Traditional coronary risk factors
Individuals with renal impairment usually have com-
plex medical histories consisting of multiple comorbidi-
ties, and several studies have documented an increasing
prevalence of traditional coronary risk factors with re-
duced renal function [4, 12, 13]. Atherosclerotic disease
in those with CKD appears to be markedly accelerated,
with more extensive anatomic disease present at younger
ages consistent with a cardiovascular risk similar to older
aged non-CKD counterparts.
Many coronary risk factors, particularly diabetes melli-
tus and hypertension, are well-established predictors for
renal disease progression [20]; a bilateral relationship
exists in which conventional coronary risk factors con-
tribute to renal disease, and this decline in renal function
appears to close the loop on a vicious cycle whereby pro-
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Fig. 2. Relationship between atherosclerosis and CKD.
gressive renal decline heightens the potency of traditional
and novel risk factors promoting accelerated atheroscle-
rosis (Fig. 2). Although CV risk attributed to CKD has
been found to be independent of various comorbidities,
the significant CV risks associated with diabetes and hy-
pertension still persist among those with CKD [4].
Dyslipidemia is a common finding among CKD cohorts
[21]. Worsening CKD is associated with changes in lipid
profiles. In mild to moderate stages of CKD, low high-
density lipoprotein (HDL) levels, increased triglycerides,
and increased levels of intermediate density lipoproteins
are often noted [8, 22]. As CKD approaches ESRD,
there appears to be increased oxidation of low-density
lipoprotein (LDL), with progressive lowering of total
cholesterol levels. The influence of dyslipidemia upon CV
outcomes appears to demonstrate a “U”-shaped relation-
ship, with increased CV event rates seen among those
with severe CKD (i.e., ESRD) having low cholesterol lev-
els [8]. Explanations for this “low cholesterol paradox”
have been attributed to the effects of chronic malnutri-
tion and inflammation, which become increasingly im-
portant with severe CKD [4, 23, 24]. In this context, the
“U”-shaped relationship of cholesterol level for CV out-
comes probably reflects the interplay of two mechanisms:
at mild to moderate stages of CKD, high cholesterol lev-
els are a contributing factor toward atherosclerosis [4],
while in severe CKD, low cholesterol levels are probably
identifying malnourished individuals with a high burden
of chronic inflammatory activity [23] and already estab-
lished atherosclerosis. This paradox in ESRD has raised
the question of utility of lipid-lowering therapy. How-
ever, recent data confirms higher risk of moderate CKD
in statin trials and similar CV risk reduction [25, 26].
Nonconventional risk factors
Conventional coronary risk factors alone cannot ex-
plain the significantly elevated CV risk and predisposition
for adverse CV outcomes. Evidence for this stems from
documented discrepancies between calculated Framing-
ham coronary point scores, which seem to underestimate
CV risk, compared with actual CV event rates [11, 27].
Following adjustment for conventional coronary risk fac-
tors, reduced renal function has consistently been asso-
ciated independently with significantly higher mortality
and adverse CV event rates [28, 29]. Progressive cardio-
vascular risk associated with worsening renal function
unexplained by known risk factors requires a broader
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Table 2. Proposed factors associated with increased CV risk with
worsening CKD
Conventional
Age
Male gender
Hypertension
Diabetes
Dyslipidemia
Smoker
Uremic
Lower creatinine clearance or eGFR
Albuminuria
Lower serum albumin
Anemia
Vascular
Reduced vascular compliance
Other
Homocysteine, inflammation, oxidative stress
Ca2+ PO43− procoagulation
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
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Fig. 3. Increasing risk for CV death with worsening albuminuria. From
Hillege et al, Circulation, 2002.
understanding of other factors that become increasingly
important with renal decline (Table 2). Nonconventional
factors that have received a lot of attention include associ-
ations with inflammation, albuminuria, anemia, reduced
vascular compliance, and homocysteine.
Inflammation. Atherosclerosis is an inflammatory dis-
order [30]. Several large cross-sectional studies have iden-
tified C-reactive protein (CRP) as an independent risk
factor for cardiac disease [31]. CRP levels provide an
overall measure of systemic inflammatory activity; they
increase dramatically in response to cytokine-mediated
stimuli and appear to have fairly constant fractional clear-
ance rates among normal subjects [32].
Several studies have documented increases in proin-
flammatory cytokines, elevated CRP levels, increased
oxidative stress, reduced clearance of proinflammatory
substances such as advanced glycosylation end products
and products of carbonyl stress [33, 34] among both pre-
dialysis and dialysis patients [23, 35]. These have all been
strongly and independently linked with increasing rates
of cardiovascular morbidity and mortality [35]. CRP is a
particularly attractive candidate of augmenting CV risk in
CKD because it has been implicated as not just a marker,
but as an actual promoter of atherosclerotic disease pro-
gression [36].
In addition, inflammation has also been linked to al-
terations in protein metabolism. Many individuals with
severe CKD suffer from malnutrition, which is partly
explained by excessive protein losses coupled to an el-
evated catabolic state [37]. Malnutrition as reflected by
low serum albumin levels have been shown to strongly
predict adverse outcomes among individuals with CKD,
particularly those receiving renal replacement therapies
[38]. Additionally, independent of nutritional status, albu-
min is also a negative acute phase protein whose synthesis
decreases during inflammation [39].
Anemia. Anemia is an independent predictor for re-
nal disease progression because it may reflect progressive
erythropoietin deficiency and the negative influence of
increasing uremic factors upon erythropoiesis with renal
decline [40]. Chronic anemia has been demonstrated to
be an independent risk factor for adverse CV outcomes,
particularly in patients with kidney disease and in pa-
tients with heart failure [41]. Anemia is associated with
left ventricular (LV) dilatation, left ventricular hypertro-
phy (LVH), and death in patients with CKD [41]. The
mechanism for this association is unclear; however, it has
been postulated that the presence of anemia may be signi-
fying an acute phase response and systemic inflammatory
activity rather than a direct effect, per se [41], in addition
to the augmentation in cardiac workload.
Albuminuria. Several retrospective and prospective
studies have consistently demonstrated that worsening
albuminuria is paralleled by increasing cardiovascular
complications [42–44]. A plausible explanation for these
findings is that albuminuria not only reflects glomerular
damage, but is also a sensitive indicator of generalized
atherosclerotic-mediated capillary vasculopathy [43, 44].
Albuminuria has been shown to cluster with a number
of vascular risk factors inclusive of hypertension, renal
dysfunction, dyslipidemia, hyperhomocysteinemia, and
several inflammatory markers [42]. After adjustment for
these factors, albuminuria is an independent predictor for
adverse CV events, and this risk increases in a continu-
ous fashion [45]. The precise mechanism underlying this
is currently unknown; several derangements in the fibri-
nolysis and coagulation systems have been noted favoring
a thrombogenic state [45].
Vascular compliance. Individuals with CKD are noted
to have evidence of reduced vascular compliance [46].
Reduced vascular compliance, as evidenced by elevated
aortic pulse wave velocities, has been demonstrated to
be a significant predictor for adverse CV events [47,
48], and several studies have also shown that widened
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pulse pressure is also an independent predictor for car-
diovascular and all cause mortality, both of which have
been shown to progressively worsen with renal decline
[49]. In a study involving 1290 untreated hypertensive
patients with mild to moderate CKD, an inverse correla-
tion with renal function independent of blood pressure
and other traditional coronary risk factors was seen with
aortic pulse wave velocity [50]. The effect of calcium on
CV risk in individuals with ESRD has been studied and
contributes to reduced vascular compliance [51]. Eleva-
tions in the calcium-phosphate product associated with
secondary hyperparathyroidism lead to vascular calcifi-
cation [51]; this has not been demonstrated in individuals
with CKD, who usually have normal calcium/phosphate
homeostasis. Mechanisms as to why vascular compliance
is reduced and/or arterial stiffness progressively increases
with worsening renal function are still being elucidated.
Homocysteine. The metabolism of homocysteine and
other sulfur-containing amino acids has been shown to be
abnormal with renal decline [52]. Among patients with se-
vere CKD, every 1 lmol increase in plasma homocysteine
levels has been shown to be independently associated
with a 1% risk for vascular events [52]. The mechanism
by which elevated homocysteine levels cause vascular dis-
ease is unknown; it may be related to endothelial dys-
function, platelet hyper-reactivity, and/or abnormalities
involving the coagulation cascade [3]. Among individu-
als with hyperhomocysteinemia and vascular events, but
without CKD, lowering of homocysteine levels is associ-
ated with reduced risk for further CV events. However,
the same relationship does not seem to hold true among
those with severe CKD; in particular, these patients seem
to be resistant to conventional homocysteine-lowering
therapies, and among those where the level is reduced,
only marginal benefits in reducing CV events have been
noted [3].
Underuse of risk modifying strategies
Despite the higher risk of major CV events and death,
the proportion of individuals with CKD receiving ap-
propriate risk factor modification and/or interventional
strategies is lower than the general population, a concept
termed “therapeutic nihilism” [2]. This reduced use of
proven therapies must be considered as a significant ia-
trogenic factor contributing to their increased CV risk.
Several databases and registries have consistently ob-
served a reduced use of proven therapies with worsening
renal function [12, 53, 54]. In patients with severe CKD
who are known to be at extreme CV risk, less than 50%
are on the combination of aspirin, b-blocker, ACE in-
hibitors, and statins [55]. Potential explanations, whether
justified or not, include concerns of worsening existing
renal function, and/or therapy-related toxic effects due
to low clearance rates [2, 56]. Bleeding concerns with
the use of platelet inhibitors and anticoagulants are espe-
cially important with reduced renal function and appear
to contribute to the decreased likelihood of patients with
severe CKD to receive aspirin and/or clopidrogrel [54].
However, several studies have shown that when appro-
priately titrated and monitored, cardiovascular medica-
tions and coronary revascularization used in the general
population can be safely administered to those with renal
impairment, and with similar benefits [55, 57].
CONCLUSION
Chronic kidney disease is a potent harbinger for
adverse cardiovascular outcomes, incorporating both
conventional and nonconventional cardiovascular risk
factors. Ironically, although awareness of this high risk
is being appreciated, application of strategies for reduc-
ing their cardiovascular morbidity and mortality seem to
be limited when compared with non-CKD cohorts. CKD
patients seem to derive as much, if not more, benefit from
such established cardiovascular therapies and strategies.
Greater efforts are needed to reduce this therapeutic gap.
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